NR1I2 and liver cancer: Both preclinical in vitro and clinical studies showed that PXR upregulation decreased the efficacy of the anticancer drugs sorafenib and doxorubicin by a mechanism known as TGF-β-induced chemoresistance in liver cancer [97].